Welcome to our dedicated page for Coeptis Therapeutics news (Ticker: COEP), a resource for investors and traders seeking the latest updates and insights on Coeptis Therapeutics stock.
News and press releases about Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) highlight its evolution as a biopharmaceutical and technology company, its cell therapy platforms, and its corporate transactions. Company announcements describe Coeptis as operating biopharmaceutical divisions focused on cell therapy platforms for cancer, autoimmune, and infectious diseases, alongside a Technology Division built around AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group.
Recent news has emphasized developments in Coeptis’ pipeline and partnerships. The company has reported securing exclusive worldwide development and commercialization rights to the GEAR Cell Therapy Platform and forming GEAR Therapeutics, Inc. to advance GEAR-modified NK cells for a broad range of cancers. SNAP Biosciences, a majority-owned subsidiary, has announced a licensing agreement with Monarch Therapeutics to enhance the SNAP-CAR NK cell therapy platform using small-molecule adaptor technology.
Coverage also includes updates on Coeptis’ hybrid business model and technology initiatives. Articles describe how the NexGenAI platform contributes revenue while the company advances its cell therapy research, and how a co-working technology hub in India supports AI, blockchain, and digital transformation projects for the NexGenAI Affiliates Group.
Another key theme in recent news is corporate strategy and capital structure. Coeptis has announced the extinguishment of a convertible note with YA II PN, Ltd, and multiple releases detail a proposed merger with Z Squared Inc., a Dogecoin-focused digital asset mining company. These items cover the filing and effectiveness of a Form S-4 registration statement, the planned spin-out of biopharmaceutical operations, and the intention for the combined company to focus on digital asset mining. Investors and observers can use this news stream to follow Coeptis’ biopharmaceutical progress, technology partnerships, financing actions, and the status of its planned merger with Z Squared.
Coeptis Therapeutics (NASDAQ: COEP) has secured exclusive worldwide rights to develop and commercialize the GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform, expanding from its previous co-development rights. The company has formed GEAR Therapeutics, a majority-owned subsidiary, to advance GEAR-modified natural killer cells (GEAR-NK) into human trials.
The GEAR-NK technology represents a novel cancer treatment approach, allowing modified NK cells to be used alongside monoclonal antibodies (mAbs) without being neutralized - a common limitation in current treatments. The platform also shows potential for modifying hematopoietic stem cells to improve bone marrow transplant outcomes in hematological malignancies.
The technology was licensed from VyGen-Bio, Inc., with research origins at Sweden's Karolinska Institutet. According to Dr. Evren Alici, COEP Scientific Advisory Board member, pre-clinical proof-of-concept data suggests GEAR-NK could reduce NK cell fratricide while improving clinical benefits in treatments like CD38 mAbs for multiple myeloma.
COEPTIS (Nasdaq: COEP) has announced a strategic partnership between its NexGenAI Affiliates Network (NexGen) and NUBURU (NYSE: BURU), a blue laser technology company. The collaboration is part of NUBURU's Transformation Plan, led by Executive Chairman Alessandro Zamboni, focusing on defense-tech, security, and operational resilience solutions.
NexGen will support NUBURU by implementing AI-driven capabilities and robotic process automation to enhance marketing strategies and B2B sales processes, particularly in the defense and security sector. NUBURU aims to leverage its laser-technology expertise and recent investments to enable growth across its subsidiaries and strategic ventures.
The partnership will utilize NexGen's advanced platform, which employs AI algorithms and data analytics to optimize marketing strategies and enhance customer engagement. NUBURU's strategy involves positioning itself as a blitz-scaling enabler through the adoption of exponential technologies.
NUBURU (NYSE: BURU), a high-power industrial blue laser technology company, has announced a strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ: COEP) as part of its comprehensive Transformation Plan. The initiative, led by Executive Chairman Alessandro Zamboni, aims to enhance operational efficiency and revamp the company's business model.
The Transformation Plan focuses on leveraging NUBURU's blue-laser technology expertise while pursuing strategic acquisitions and commercial alliances. The partnership with NextGen will specifically target the enhancement of marketing and B2B sales processes, particularly in the defense and security sector, where NUBURU sees significant growth opportunities.
NextGen's platform will contribute advanced AI algorithms and data analytics to optimize marketing strategies and enhance customer engagement. This collaboration represents a key step in NUBURU's strategy to position itself as a tech and business growth enabler for its future subsidiaries and strategic ventures.
COEPTIS (Nasdaq: COEP) has announced a strategic partnership between its NexGenAI Affiliates Network and Arketyp Valu, a developer within the Verus Project ecosystem. The collaboration aims to integrate NexGenAI's digital marketing solutions into the upcoming ValuSocial platform, leveraging Verus Coin's blockchain technology and Public Blockchains as a Service (PBaaS).
The Verus Project, which has recently achieved a market capitalization exceeding $500 million, will provide the foundation for ValuSocial's fully immersive environment. The platform will enable users to launch targeted digital campaigns combining marketing strategies with blockchain technology, facilitating engagement through digital tokens.
Nicholas Lyons, CEO of Arketyp Valu, and Dave Mehalick, CEO of COEPTIS, both expressed enthusiasm for the partnership, highlighting its potential to create a decentralized digital ecosystem that delivers value to users and businesses globally.
Coeptis (Nasdaq: COEP) has announced a strategic partnership between its NexGenAI Affiliates Network and MarketLeverage, combining AI technology with performance-based marketing strategies. The collaboration connects NexGenAI's AI-powered platform with MarketLeverage's network of 5,500 advertisers and 55,000 publishers.
The partnership provides access to AI-driven campaign management, predictive analytics, and automated outreach capabilities. NexGenAI's platform enables affiliates to earn commissions through automated content distribution, social media sharing, and targeted email campaigns with real-time AI optimization.
The artificial intelligence marketing market is projected to grow from $27.83 billion in 2024 to $106.54 billion in 2029, with a CAGR of 31.6%. This partnership aims to enhance marketing efficiency, drive higher-quality traffic, and increase conversions through advanced automation and data-driven insights.
Coeptis (Nasdaq: COEP) has announced a strategic partnership between its NexGenAI Affiliates Network and MarketLeverage, combining AI technology with performance-based marketing strategies. The collaboration provides access to MarketLeverage's network of 5,500 advertisers and 55,000 publishers, creating one of the industry's most extensive affiliate networks.
The partnership integrates AI-driven campaign management, predictive analytics, and automated outreach capabilities. Affiliates will earn commissions through automated content distribution, social media sharing, and targeted email campaigns, with AI optimizing performance in real-time.
The artificial intelligence marketing market is projected to grow from $27.83 billion in 2024 to $106.54 billion in 2029, with a CAGR of 31.6%.
COEPTIS (Nasdaq: COEP) has announced the launch of COEP Venture Group, a new investment arm focused on funding startups specializing in Artificial Intelligence, Robotic Process Automation, and AI Agents. The venture group will be led by Michael Woloshin, co-founder of Recruiter.com and founder of NexGenAI Solutions Group.
The investment focus includes advanced machine learning models, AI-powered automation for workflow optimization, autonomous AI-powered assistants, and emerging technologies like blockchain applications. COEP Venture Group will provide capital, strategic mentorship, and industry network access to portfolio companies, while leveraging NexGenAI Solutions Group to provide marketing services.
This initiative expands COEPTIS's existing portfolio, which includes biopharmaceutical divisions focusing on cell therapy platforms for cancer, autoimmune, and infectious diseases, featuring assets licensed from Deverra Therapeutics and partnerships with VyGen-Bio and the Karolinska Institute.
COEPTIS (NASDAQ: COEP) has successfully completed its Series A Preferred financing round, raising an additional $5.7 million for a total of $10 million. The latest funding was led by CJC Investment Trust, controlled by board member Christopher Calise. The Series A Preferred is convertible to common stock at $8.00 per share, with investors receiving a 15% equity stake in two newly formed subsidiaries: SNAP Biosciences and GEAR Therapeutics.
The financing follows an initial closure of $4.3 million in June 2024. Funds will be used to strengthen the company's balance sheet, repay obligations, and support general corporate purposes. Notably, the capital will accelerate COEPTIS' integration of AI solutions and automation capabilities, particularly through their recently acquired NexGenAI Affiliates Network platform, aimed at enhancing research processes and operational efficiency in the biopharmaceutical sector.
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced its rebranding to COEPTIS, signaling a strategic expansion beyond biopharmaceuticals into technology-driven sectors. The company has established a new Technology Division, marked by the acquisition of the NexGenAI Affiliates Network platform, an AI-powered marketing solution.
The transformation aims to enhance operational capabilities and maximize shareholder value through technology integration. The NexGenAI platform will provide AI-driven marketing solutions for highly regulated industries, while the Technology Division focuses on developing automation capabilities and AI agents to optimize workflows.
According to CEO Dave Mehalick, this strategic shift aims to create revenue-generating, cash flow-positive business units, positioning COEPTIS as a self-sustaining entity. The company's technology suite includes AI-driven marketing software, robotic process automation (RPA), and data analytics tools designed to enhance communication strategies and drive sustainable growth.
Coeptis Therapeutics Holdings (Nasdaq: COEP), a biopharmaceutical company specializing in cell therapy platforms, has announced the expansion of its technological initiatives to include artificial intelligence and blockchain solutions. Following the successful launch of its Technology Division, the company aims to enhance operational efficiency and customer engagement through these advanced technologies.
CEO Dave Mehalick expressed enthusiasm about building upon the momentum generated by their Technology Division, particularly in AI, while exploring blockchain opportunities. The company views this expansion as a strategic move to remain at the forefront of technological developments and adapt to the evolving digital marketplace.